The global Multivalent Vaccines market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025.
This report focuses on Multivalent Vaccines volume and value at global level, regional level and company level. From a global perspective, this report represents overall Multivalent Vaccines market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Multivalent Vaccines in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Multivalent Vaccines manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
GlaxoSmithKline, plc (U.K.)
Pfizer, Inc. (U.S.)
Merck & Co., Inc. (U.S.)
Sanofi Pasteur SA (France)
Astellas Pharma Inc. (Japan)
CSL Limited (Australia)
Emergent BioSolutions, Inc. (U.S.)
Johnson & Johnson (U.S.)
MedImmune, LLC (U.S.)
Serum Institute of India Pvt. Ltd. (India)
Bavarian Nordic (Denmark)
Mitsubishi Tanabe Pharma Corporation (Japan)
Daiichi Sankyo (Japan)
Protein Sciences Corporation (U.S.)
Panacea Biotec (India)

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
Conjugate Vaccines
Inactivated and Subunit Vaccines
Live Attenuated Vaccines
Toxoid Vaccines
Recombinant Vaccines

Segment by Application
Pediatrics
Adults